| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
IC50: ~30 μM (KATP)
The primary target of 5-Hydroxydecanoate sodium is the mitochondrial ATP-sensitive potassium channel (mitoKATP), a channel located in the inner mitochondrial membrane. By selectively inhibiting mitoKATP, 5-HD sodium prevents the opening of these channels, which are believed to play a protective role during ischemic preconditioning. The compound is a substrate for mitochondrial outer membrane acyl-CoA synthetase and exhibits an IC50 of approximately 30 μM for KATP channel inhibition. Its specificity for mitoKATP over sarcKATP makes it an essential tool for dissecting the distinct roles of these channel subtypes. |
|---|---|
| ln Vitro |
The protective effect of penehyclidine hydrochloride (PHC) pretreatment on anoxia/reoxygenation (A/R)-induced H9c2 cell damage was eliminated by 5-Hydroxydecanoate (5-HD) treatment. 5-Hydroxydecanoate inhibits PHC's inhibitory action on ROS generation and Ca2+ overload. 5-Hydroxydecanoate encourages Cyt-C to be released into the cytoplasm from mitochondria. 5. Hydroxydecanoate reduces PHC's anti-apoptotic activity. Following PHC treatment, there was a notable rise in Bcl-2 levels and a significant drop in Bax and cleaved caspase-3 levels. 5. Pretreatment with hydroxydecanoate may counteract the impact of PHC on its expression level. Five-hydroxydecanoate inhibits PHC's impact on KATP channels [1].
In vitro, 5-Hydroxydecanoate sodium is used to study the role of mitoKATP channels in cellular physiology. It inhibits the proliferation of hypoxic human pulmonary artery smooth muscle cells (HPASMC) by blocking mitochondrial KATP channels. The compound blocks the inhibitory effect of preconditioning agents on calcium overload and reactive oxygen species (ROS) production. At standard working concentrations of 50-100 µM, 5-HD sodium abolishes the infarct-sparing effects of ischemic preconditioning. It also promotes the release of cytochrome C from mitochondria into the cytoplasm, indicating its role in mitochondrial permeability transition. |
| ln Vivo |
5-Hydroxydecanoate (100 μM) therapy prevented the effects of ischemia preconditioning (IPC) on contractile recovery in rats, while leaving intact its effects on contracture, lactate generation, glycogenolysis, and viable tissue [3].
In vivo, 5-Hydroxydecanoate sodium is used to investigate the role of mitoKATP channels in various pathophysiological conditions. It has been studied for its potential therapeutic applications in myocardial ischemia, neurodegenerative diseases, and metabolic disorders. By selectively blocking mitoKATP channels, the compound can be used to determine the contribution of these channels to cardioprotection and neuroprotection. In animal models, 5-HD sodium is often administered prior to an ischemic event to assess the role of mitoKATP channels in preconditioning-mediated protection against tissue damage. |
| Enzyme Assay |
In vitro assays for 5-Hydroxydecanoate sodium typically involve the use of isolated mitochondria or cultured cells to assess mitoKATP channel function. Mitochondrial membrane potential can be measured using fluorescent dyes such as JC-1 or TMRM, and the effects of 5-HD sodium on membrane potential changes induced by mitoKATP channel openers (like diazoxide) are assessed. In cell-based assays, 5-HD sodium is used to block the protective effects of preconditioning against hypoxia-reoxygenation injury, with endpoints including cell viability (MTT assay), ROS production, and cytochrome c release. The compound is typically dissolved in aqueous physiological buffers up to 100 mM.
|
| Cell Assay |
Cellular assays for 5-Hydroxydecanoate sodium often utilize cardiomyocytes, neurons, or pulmonary artery smooth muscle cells. For example, in hypoxic human pulmonary artery smooth muscle cells (HPASMC), 5-HD sodium inhibits proliferation by blocking mitoKATP channels. In cardiomyocytes, the compound is used to study the mitochondrial pathways involved in ischemic preconditioning. Cells are pretreated with 5-HD sodium (typically 50-100 µM) prior to exposure to hypoxia or metabolic stress. Endpoints include cell survival, mitochondrial membrane potential, ROS production, and the release of apoptotic factors.
|
| Animal Protocol |
In vivo animal studies for 5-Hydroxydecanoate sodium are often conducted in rodent models of myocardial ischemia-reperfusion injury. The compound is administered intravenously or intraperitoneally prior to ischemia, and its effects on infarct size, cardiac function, and biochemical markers of injury are assessed. In models of neurodegenerative diseases, 5-HD sodium may be administered to study the role of mitoKATP channels in neuronal survival. The compound's selectivity for mitoKATP allows researchers to specifically investigate the contribution of these channels to the protective effects of preconditioning and other therapeutic interventions, distinguishing them from sarcolemmal KATP channels.
|
| ADME/Pharmacokinetics |
5-Hydroxydecanoate sodium does not have conventional pharmacokinetic properties as it is used as a research tool rather than a therapeutic agent. It is a small, water-soluble compound that can be readily administered in aqueous solutions. The sodium salt form ensures rapid, complete dissolution in aqueous physiological buffers. Its distribution is likely determined by its small size and polarity, and it is thought to be taken up by cells and mitochondria where it exerts its inhibitory effects on mitoKATP channels. The compound is typically used at concentrations of 50-100 µM in vitro and at doses determined experimentally in vivo.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for 5-Hydroxydecanoate sodium in the available literature. As a research chemical intended for laboratory use only, it should be handled with standard safety precautions for handling chemical reagents. The compound is not approved for human therapeutic use. Researchers should consult the material safety data sheet (MSDS) for detailed safety and handling information. Any potential toxicity would need to be assessed through formal toxicological studies if the compound were to be developed further.
|
| References |
|
| Additional Infomation |
5-Hydroxydecanoate sodium (5-HD sodium) is a selective, water-soluble inhibitor of the mitochondrial ATP-sensitive potassium channel (mitoKATP). It has a molecular formula of C10H19NaO3 and a molecular weight of 210.25 g/mol. The compound selectively inhibits mitoKATP with an IC50 of approximately 30 μM. It is used as a pharmacological tool to distinguish between mitochondrial and sarcolemmal KATP channels and has been studied in myocardial ischemia, neurodegenerative diseases, and metabolic disorders. Unlike glibenclamide, 5-HD sodium does not block sarcolemmal KATP channels.
|
| Molecular Formula |
C10H19NAO3
|
|---|---|
| Molecular Weight |
210.25
|
| Exact Mass |
210.123
|
| CAS # |
71186-53-3
|
| PubChem CID |
23676659
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
320.8ºC at 760 mmHg
|
| Flash Point |
162ºC
|
| LogP |
0.847
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
14
|
| Complexity |
139
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCC(CCCC(=O)[O-])O.[Na+]
|
| InChi Key |
YNAGNECWEKMWRM-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C10H20O3.Na/c1-2-3-4-6-9(11)7-5-8-10(12)13;/h9,11H,2-8H2,1H3,(H,12,13);/q;+1/p-1
|
| Chemical Name |
sodium;5-hydroxydecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 12.5 mg/mL (59.45 mM)
H2O: 10 mg/mL (47.56 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (5.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (5.95 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (5.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 6.25 mg/mL (29.73 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7562 mL | 23.7812 mL | 47.5624 mL | |
| 5 mM | 0.9512 mL | 4.7562 mL | 9.5125 mL | |
| 10 mM | 0.4756 mL | 2.3781 mL | 4.7562 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
